Department of Endocrinology, the Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, Jiangxi Province, 330006 Nanchang, China.
Department of Endocrinology, the Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, Jiangxi Province, 330006 Nanchang, China.
Ann Endocrinol (Paris). 2019 Apr;80(2):128-133. doi: 10.1016/j.ando.2018.11.002. Epub 2019 Jan 29.
In the modern world, type-2 diabetes mellitus has become a leading public healthcare problem, due to major risks of morbidity and mortality. Prevalence has increased significantly in recent decades. Treatment involves oral hypoglycemic agents or insulin replacement therapy. Development is ongoing for cell-based diabetes therapies using stem cells with the potential to differentiate into insulin-producing cells (IPCs): embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and stem cells from adult pancreas, liver, central nervous system, bone marrow and adipose tissue. Successful induction of iPSCs, however, depends on the quantity and quality of available stem cells and the development of adapted protocols determining the environment of extrinsic factors and involvement of small molecules. Validating such new cell therapies must be founded on this experimental rationale.
在现代社会，2 型糖尿病已成为主要的公共卫生保健问题，因为它存在严重的发病和死亡风险。近年来，其发病率显著上升。治疗方法包括口服降糖药或胰岛素替代疗法。目前正在开发基于细胞的糖尿病疗法，使用具有分化为胰岛素分泌细胞（IPCs）潜力的干细胞：胚胎干细胞（ESCs）、间充质干细胞（MSCs）、诱导多能干细胞（iPSCs），以及来自成人胰腺、肝脏、中枢神经系统、骨髓和脂肪组织的干细胞。然而，iPSCs 的成功诱导取决于可用干细胞的数量和质量，以及开发适应的方案来确定外在因素的环境和小分子的参与。这种新的细胞疗法的验证必须建立在这一实验原理的基础上。
